Determinants and outcomes of bloodstream infections related to obesity

Felicity Edwards1 · Kate Glen3 · Patrick N. A. Harris4,5 · David L. Paterson4,6 · Kevin B. Laupland1,2

Received: 3 July 2022 / Accepted: 19 September 2022 / Published online: 4 October 2022
© The Author(s) 2022

Abstract
Although obesity is a major healthcare problem that is increasing in many populations worldwide, there are limited studies that have examined its contribution to infectious diseases morbidity and mortality. The aim of this study was to examine the clinical determinants and outcomes of bloodstream infections among patients with obesity. All adults within the publicly funded healthcare system in Queensland, Australia, identified with a BSI during 2017–2019 were included and the presence of obesity was based on discharge International Classification of Diseases (ICD-10) codes. Clinical features, microbiology, and outcomes were compared among obese and non-obese subjects. A total of 24,602 incident BSI were identified among 21,613 Queensland residents; of which 4,579 (21.2%) and 17,034 (78.8%) were classified as obese or non-obese, respectively. Obese patients were less likely to have community associated infections and were more likely to be younger, female, have higher comorbidity scores, and have bone and joint or soft tissue infections as compared to non-obese subjects. Obese patients had a lower proportion of Escherichia coli BSI and higher proportions of b-haemolytic streptococci. Although obese patients had longer hospital admissions and more repeat incident BSI within 1 year, they had lower overall case fatality. In a logistic regression model, obesity was associated with a lower risk for 30-day case fatality (adjusted odds ratio 0.51, 95% confidence interval 0.45–0.58). Obesity is associated with significant differences in the determinants and outcome of BSI. Increasing rates of obesity is likely to influence the epidemiology of BSI in populations.

Keywords Obesity · Bloodstream infections · BSI · Epidemiology

Introduction
Obesity is recognized as a major risk factor for adverse health effects and outcomes, and is increasing in many populations worldwide [1–3]. Excess body weight may predispose an individual to an increased risk of infections as a result of physiologic effects including decreased functional residual capacity, altered immunity, and chronic inflammation as well as associated comorbidities including diabetes, cardiovascular disease, chronic kidney disease, cancer, and liver disease [2, 3]. Studies conducted in critically ill populations have demonstrated that obesity is an independent risk factor for acquiring central line associated infections, and that septic obese patients are more likely to have Gram-positive organisms from skin or soft tissue foci as compared to non-obese patients [4–6]. Other studies in hospitalized patients have found that obesity increased the risk for nosocomial BSI more than fivefold [7], and increased length of stay among those with candidemia [8]. It is not well defined as
to whether obesity per se increases the risk of dying from serious infection [9, 10].

Although obesity is common and associated with a range of adverse health effects, there is a limited body of literature investigating obesity in relation to serious infections. Most studies have included only small numbers of subjects or have been limited to highly selected patient cohorts [7–9, 11, 12]. The objective of this study was to examine the determinants and outcomes of patients with BSI associated with obesity in a large Australian population.

Methods

The study population comprised of all residents of Queensland, Australia, who were identified as having incident BSI and were admitted to a Queensland Health public hospital between January 1st, 2017, and December 31st, 2019. Queensland’s publicly funded health system, Queensland Health, services approximately 1.6 million episodes of care annually across 16 hospital and healthservice (HHS) regions within a population of approximately 5 million residents [13]. Approval for this study was granted with waiver of individual consent by the Human Research Ethics Committee at the Royal Brisbane and Women’s Hospital (LNR/2020/QRBW/62494).

Pathology Queensland performed all statewide blood culture testing for both community and institutional collection sites across Queensland Health. Throughout the study, all processing sites used the BACT/Alert® 3D system (bioMérieux, Durham, NC) apart from the main central laboratory managing culture submissions from the Greater Brisbane Area and several rural Queensland sites which used the BACT/ALERT® VIRTUO® system (bioMérieux, Durham, NC) during 2018. All blood cultures were incubated using BacT/ALERT FA plus (aerobic), and FN plus (anaerobic) media bottles for 5 days and subsequently discarded if no growth was detected.

The Queensland Health Clinical Information Systems Support Unit (CISSU) retrospectively identified all blood cultures which produced bacterial growth throughout the study period. Culture results (unique laboratory number, date and time of draw, and species identification) were obtained along with demographic (date of birth, gender, and postal code) details. Incident BSIs were differentiated by first and subsequent bacterial isolations per patient, with the first and subsequent isolation of the same species within 30 days deemed to represent the same episode of BSI. Polymicrobial infections were those where a bacterial species was co-isolated with one or more other significant pathogens within a 48-h period with two independent sets required for common contaminants in order to define significance [14].

Once incident episodes were identified, linkages with statewide databases were used to obtain additional clinical and outcome information. Encounters 2 years preceding and 1 year following an index blood culture were identified within Queensland Hospital Admitted Patient Data Collection (QHAPDC) and used to determine hospital admission and discharge dates, discharge survival status, geographical location, and ICD-10-AM diagnostic codes. The diagnosis of obesity was determined using the following codes “E660” or “E661” or “E6610” or “E6611” or “E6612” or “E6613” or “E662” or “E6620” or “E6621” or “E6622” or “E6623” or “E668” or “E669” or “E6690” or “E6691” or “E6692” or “E6693” or “U781.” For the purposes of length of stay, episodes observed within multiple continous hospital admissions (such as inter-hospital transfers) were deemed to represent a single hospital admission. The Registry of General Deaths was queried as of December 31, 2020, to confirm institution-based deaths and those occurring in other settings within Queensland. The Accessibility/Remoteness Index of Australia (ARIA +) was used to determine geographical remoteness of the study population based on their accessibility to goods, services, opportunities, and road distance measurements from over 12,000 populated localities to the nearest Service Centres in five size categories based on population size [15].

Bloodstream infections were classified as hospital onset, healthcare associated, or community associated as previously described [16]. Comorbid illnesses were defined using the Charlson comorbidity index and were established using validated coding dictionaries [17, 18]. A clinical focus was assigned based on review of diagnosis-related group and primary hospital discharge codes.

Data was analyzed using Stata 17.0 (StataCorp, College Station, USA). Medians with interquartile ranges (IQR) were used to described non-normally distributed continuous variables and were compared using the Mann–Whitney-Wilcoxon test. Categorical data were compare using the Fisher’s exact test. A multivariable logistic regression model was developed to examine factors associated with all-cause 30-day case fatality rates; only first admissions were included in this analysis. Age, sex, onset classification, Charlson score, mono-versus polymicrobial infection, and focus of infection were included in the initial model. Stepwise backward variable elimination was performed in order to develop the most parsimonious model [19]. Calibration and discrimination were assessed using the Hosmer–Lemeshow test and the area under the receiver operator characteristic curve, respectively. In all statistical testing, p values of <0.05 were deemed to represent statistical significance.
Results

Description of the overall cohort

There were a total of 24,602 incident episodes of BSI among 21,613 QLD adult residents; 2,239 had two, 495 had three, and 255 had four or more incident infections during the surveillance period. The overall median age was 64.3 years (IQR, 44.5–77.0), and 10,691 (43.5%) were female. The majority of BSIs were community onset (19,725; 80.1%) of which 11,224 (45.6%) were community associated, 8,501 (34.5%) were healthcare associated, and 4,877 (19.8%) were hospital onset. Overall, 5,403 (21.9%) episodes were in those classified as obese.

Demographic determinants

There was an increasing proportion of episodes occurring among obese individuals with advancing age, peaking in the 50–59 age group and nadir in the 80+ age group. Although the distribution of obesity was similar for males and females <30 years, more males than females were obese beyond the age of 30 years (Fig. 1). There was a significant ($p < 0.001$) difference in the proportion of obesity by remoteness although this was not across ordered groups. Geographically, the proportion of obesity was 2,786/12,832 (21.7%) for metropolitan areas, 1,570/6,115 (25.7%) for inner regional areas, 825/4,414 (18.7%) for outer regional areas, 93/529 (17.6%) for remote areas, and very remote 97/438 (22.2%).

Clinical determinants

There were a number of different clinical features among BSIs occurring in obese and non-obese patients as detailed in Table 1. The onset location of infections was significantly different with obese patients having more healthcare related (i.e., healthcare associated and hospital onset infections; Table 1).

Underlying medical illnesses were common among obese patients with higher median Charlson comorbidity scores compared to non-obese. Almost one-third of non-obese patients had zero comorbidities (5,285; 27.5%), whereas obese patients with no comorbidities accounted less than one-fifth (908; 16.8%; $p < 0.001$). Charlson comorbidity scores of 1–2 were similar across both groups (1,503; 27.8% vs. 5,979; 31.1%; $p < 0.001$); however, scores of 3+ were much higher in the obese group (2,992; 55.3%) compared to the non-obese group (7,935; 41.3%; $p < 0.001$).

Overall, the most common comorbid medical conditions were diabetes, renal disease, congestive heart failure, and malignancy; however, the comorbidities varied greatly when comparing the obese vs. non-obese cohorts. Rates of renal disease and congestive heart failure were higher in obese patients, and rates of diabetes were twice as common than the non-obese group. The rates of malignancy were higher in the non-obese group and accounted for approximately one-fifth of the cohort (Table 1).

The distribution of infectious foci was different with obese patients having a greater proportion of soft tissue infections and bone and joint infections (Table 1). The etiology also demonstrated significant variability with obese patients having relatively twice as many infections due to b-hemolytic streptococci and fewer *Escherichia coli* as shown in Table 1.
Soft tissue infections were comparably higher among obese males than obese females (301; 56.9% vs. 228; 43.1%; \( p = 0.005 \)). Bone and joint infections were also more frequently obesity associated among males as compared to females (193; 61.3% vs. 122; 38.7%; \( p = 0.002 \)), although this did not associate with any age group.

Table 1 Clinical determinants of obese and non-obese patients with bloodstream infections in Queensland, 2017–2019

| Factor                              | Obese (\( n = 5403 \)) | Non-obese (\( n = 19,199 \)) | \( p \)-value |
|-------------------------------------|-------------------------|-------------------------------|---------------|
| Median age (IQR)                    | 66.3 (55.2–74.5)        | 70.5 (55.1–81.4)              | <0.001        |
| Male sex                            | 2829 (52.4%)            | 11,082 (57.7%)                | <0.001        |
| Median Charlson (IQR)               | 3 (2–5)                 | 2 (0–4)                       | <0.001        |
| Myocardial infarction               | 604 (11.2%)             | 1560 (8.1%)                   | <0.001        |
| Congestive heart failure            | 1454 (26.9%)            | 3202 (16.7%)                  | <0.001        |
| Peripheral vascular disease         | 385 (7.1%)              | 1064 (5.5%)                   | <0.001        |
| Cerebrovascular disease             | 369 (6.8%)              | 1433 (7.5%)                   | 0.114         |
| Dementia                            | 147 (2.7%)              | 1357 (7.1%)                   | <0.001        |
| Chronic pulmonary                   | 931 (17.2%)             | 2501 (13.0%)                  | <0.001        |
| Rheumatic                           | 97 (1.8%)               | 322 (1.7%)                    | 0.553         |
| Peptic ulcer disease                | 147 (2.7%)              | 371 (1.9%)                    | <0.001        |
| Liver disease                       | 663 (12.3%)             | 2196 (11.4%)                  | 0.092         |
| Diabetes mellitus                   | 2964 (54.9%)            | 5270 (27.5%)                  | <0.001        |
| Plegia                              | 266 (4.9%)              | 936 (4.9%)                    | 0.885         |
| Renal disease                       | 1687 (31.2%)            | 3764 (19.6%)                  | <0.001        |
| Malignancy                          | 802 (14.8%)             | 4036 (21.0%)                  | <0.001        |
| HIV                                 | 3 (<1.0%)               | 40 (<1.0%)                    | 0.018         |

Focus of infection

| No focus                            | 2755 (51.0%)            | 9948 (51.8%)                  | <0.001        |
| Soft tissue                         | 529 (9.8%)              | 1062 (5.5%)                   |               |
| Bone and joint                      | 315 (5.8%)              | 656 (3.4%)                    |               |
| Head and neck                       | 36 (<1.0%)              | 169 (<1.0%)                   |               |
| Lower respiratory                   | 322 (6.0%)              | 1453 (7.6%)                   |               |
| Endovascular                        | 166 (3.1%)              | 591 (3.1%)                    |               |
| Central nervous system              | 41 (<1.0%)              | 100 (<1.0%)                   |               |
| Abdominal                           | 582 (10.8%)             | 2345 (12.2%)                  |               |
| Urinary/pelvic                      | 657 (12.2%)             | 2875 (15.0%)                  |               |

Infection onset classification

| Hospital onset                      | 1219 (22.6%)            | 3658 (19.1%)                  | <0.001        |
| Healthcare associated               | 1962 (36.3%)            | 6539 (34.1%)                  |               |
| Community associated                | 2222 (41.1%)            | 9002 (46.8%)                  |               |

Etiology

| Escherichia coli                    | 1240 (23.0%)            | 5588 (29.1%)                  | <0.001        |
| Staphylococcus aureus               | 901 (16.7%)             | 2897 (15.1%)                  |               |
| b-Hemolytic streptococci            | 650 (12.0%)             | 1212 (6.3%)                   |               |
| Other Enterobacterales              | 388 (7.2%)              | 1302 (6.8%)                   |               |
| Klebsiella species                  | 317 (5.9%)              | 1280 (6.7%)                   |               |
| Pseudomonas species                 | 275 (5.1%)              | 873 (4.5%)                    |               |
| Coagulase negative staphylococci    | 224 (4.1%)              | 560 (2.9%)                    |               |
| Other Gram negatives                | 217 (4.0%)              | 920 (4.8%)                    |               |
| Other                               | 210 (3.9%)              | 874 (4.6%)                    |               |
| Anaerobes                           | 208 (3.8%)              | 804 (4.2%)                    |               |
| Enterococcus species                | 187 (3.5%)              | 604 (3.1%)                    |               |
| Pneumococcus                        | 104 (1.9%)              | 467 (2.4%)                    |               |
| Yeasts                              | 89 (1.6%)               | 319 (1.7%)                    |               |
| Polymicrobial                        | 393 (7.3%)              | 1499 (7.8%)                   |               |
Hospital admission and outcome

The median duration of hospital stay was 10 (IQR 6–25) days and the median length of hospital stay for obese patients was 3 days longer than non-obese patients (12; IQR 6–29 vs. 9; 5–21). Among the obese cohort, those with community-onset BSI, the median length of stay was 2 days longer than non-obese cohort (9; IQR 6–18 vs. 7; 4–14). Among patients incepted in 2017 and 2018, new incident BSI occurred within 1 year in 539 (10.0%) obese and 1,310 (6.8%; p < 0.0001) non-obese patients.

The crude 30-day case fatality following the initial episode was 7.5% (345/4,579) and was higher for non-obese patients (2,232/17,034; 13.1%; p < 0.001). After adjustment for confounding variables in logistic regression analysis, obesity was associated with a lower risk for 30-day case fatality (n = 21,613; area under receiver operator characteristics curve 0.7654; goodness of fit p = 1.0) as shown in Table 2.

Discussion

In this study, we report the determinants and outcomes of patients with BSI associated with obesity in an Australian population. We found older individuals, particularly males and those with comorbidities, are at a higher risk of developing BSI and the source of infection was more likely to be soft tissue or bone and joint in association with obesity. In addition, the obese cohort had longer hospital admissions and repeat incident infections particularly of b-hemolytic streptococci infections. However, the obese cohort had a lower case fatality. This study represents the largest cohort to date and adds to the relatively small published data on the epidemiology of obesity-associated BSI.

There are few previous studies that have documented excess risk for developing BSI associated with obesity. Buetti and colleagues conducted a post hoc analysis of clinical trials and found that obesity was a significant risk factor for development of central line associated infections in ICUs [4]. Kaye et al. performed a retrospective case control study and using a prediction model found that obesity was an independent risk factor for nosocomial infections in those aged over 65 years [7]. In the current study and consistent with other studies, BSI risk increased with age with a male dominance [4, 7, 8]. Two previous studies from Norway showed increased risk of BSI with increasing BMI [11, 12]. Paulsen et al. stratified BSI cases by BMI and after adjusting for age and sex, were able to show a dose-dependent increase risk of BSI starting at BMI 30 kg/m² [11]. Using a subcohort of European genotyping from the same dataset, Rogne et al. used Mendelian randomization design and showed that the genetically predicted BMI of 30 kg/m² significantly increased the risk for BSI as composed to 25 kg/m² in a population-based study [12]. Two other studies used BMI classification to assess BSI risk and showed that although obese males in their late 50 s to 70 s were more likely to have a BSI, this only applied in until BMI 39.99 kg/m², compared to the BMI > 40 kg/m² category where it appeared younger women in their late 40 s to late 50 s were more at risk [5, 9].

The increased risk for development of BSI among obese patient is likely related at least in part due to an increased risk for comorbidities that are known to be associated with excess BSI risk most notably diabetes, renal failure, and cardiovascular disease [20–22]. In contrast, malignancies and associated immune compromise may be risk factors associated with normal or low body weight. Arabi et al. reported on patients with septic shock from hospitals in Canada, USA, and Saudi Arabia and found that heart failure and diabetes were significant factors among the 850 obese patients whereas immunosuppressive disorders were associated with non-obesity [5]. A smaller Greek study of 38 obese patients found diabetes and chronic pulmonary disease were more prevalent; however, solid organ and hematologic malignancy was also more common than the non-obese cohort, but this was not significant [6]. The degree to which obesity per se modifies risk for BSI beyond that explained by comorbidities requires further investigation.

Obese patients experienced a different hospital course and outcome as compared to non-obese patients. We observed an excess length of stay of 3 days associated with obesity. Barber et al. previously reported on 80 patients (28 obese and 52

Table 2 Logistic regression analysis of factors associated with 30-day case fatality among obese patients with bloodstream infections

| Factor                        | Odds ratio | 95% CI     | p-value |
|-------------------------------|------------|------------|---------|
| Obese                         | 0.51       | 0.45–0.58  | <0.001  |
| Focus of infection            |            |            |         |
| No focus                      | 1 (reference) | -        |         |
| Soft tissue                    | 0.35       | 0.27–0.45  | <0.001  |
| Bone and joint infection      | 0.37       | 0.26–0.52  | <0.001  |
| Head and neck infection       | 0.51       | 0.25–1.01  | 0.054   |
| Lower respiratory infection   | 1.43       | 1.24–1.65  | <0.001  |
| Endovascular infection        | 0.98       | 0.75–1.28  | 0.889   |
| Central nervous system infection| 1.38     | 0.76–2.50  | 0.290   |
| Abdominal infection           | 0.65       | 0.56–0.75  | <0.001  |
| Urinary/pelvic infection      | 0.29       | 0.24–0.35  | <0.001  |
| Polymicrobial infection       | 1.54       | 1.33–1.79  | <0.001  |
| Onset classification          |            |            |         |
| Hospital onset                | 1          | -          |         |
| Healthcare associated infection| 0.70       | 0.63–0.79  | <0.001  |
| Community associated infection| 0.56       | 0.50–0.63  | <0.001  |
| Age per year                  | 1.03       | 1.03–1.03  | <0.001  |
| Charlson comorbidity index    | 1.22       | 1.20–1.24  | <0.001  |
of obesity is likely to influence the epidemiology of BSI in populations, and further efforts to reduce the burden of obesity-associated infections are warranted.

**Author contribution** Conception and design (K.B.L., D.L.P., P.H.), acquisition of data (K.B.L., F.E., P.H., D.L.P.), analysis and interpretation of data (K.B.L., F.E.), and manuscript preparation (K.B.L., F.E., K.G., P.H., D.L.P.).

**Funding** Open Access funding enabled and organized by CAUL and its Member Institutions P.H. participated as an advisory board member for both MSD and Sandoz, and payment was paid to the University of Queensland. P.H. also received an honorarium paid to the University of Queensland.

**Data availability** Data cannot be shared publicly due to institutional ethics, privacy, and confidentiality regulations. Data release for the purposes of research under Sect. 280 of the Public Health Act 2005 requires application to the Director General (PHA@health.qld.gov.au).

**Declarations**

**Ethics approval and consent to participate** The Human Research Ethics Committee at Royal Brisbane and Women’s Hospital approved this study and granted a waiver of individual consent (LNR/2020/QRBW/62494).

**Conflict of interest** The authors declare no competing interests.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. CDC - National Center for Health Statistics. Health effects of overweight and obesity 2022. Available from: https://www.cdc.gov/healthyweight/effects/index.html. Accessed 16 May 2022
2. Schetz M, De Jong A, Deane AM, Druml W, Hemelaar P, Pelosi P et al (2019) Obesity in the critically ill: a narrative review. Intensive Care Med 45(6):757–769
3. World Health Organisation. Obesity 2022. Available from: https://www.who.int/health-topics/obesity#tab=2. Accessed 16 May 2022
4. Buetti N, Souweine B, Mermel L, Minoz O, Ruckly S, Lioiodie A et al (2021) Obesity and risk of catheter-related infections in the ICU. A post hoc analysis of four large randomized controlled trials. Intensive Care Med 47(4):435–43
5. Arabi YM, Dara SI, Tamim HM, Rishu AH, Bouchama A, Khedr MK et al (2013) Clinical characteristics, sepsis interventions and

---

**Conclusion**

This study identifies that the clinical characteristics, course in hospital, and outcomes associated with BSI are different among obese and non-obese patients. This study adds to the growing body of literature documenting the adverse effects of obesity on infectious disease mortality. Increasing rates of obesity-associated infections are warranted.
outcomes in the obese patients with septic shock: an international multicenter cohort study. Crit Care 17(2):R72
6. Papadimitriou-Oliveros M, Aretha D, Zotou A, Koutsileou K, Zbouki A, Lefkaditi A et al (2016) The role of obesity in sepsis outcome among critically ill patients: a retrospective cohort analysis. Biomed Res Int 2016:5941279
7. Kaye KS, Marchaim D, Chen TY, Chopra T, Anderson DJ, Choi Y et al (2011) Predictors of nosocomial bloodstream infections in older adults. J Am Geriatr Soc 59(4):622–627
8. Barber KE, Wagner JL, Miller JM, Lewis EA, Stover KR (2020) Impact of obesity in patients with Candida bloodstream infections: a retrospective cohort study. Infect Dis Ther 9(1):175–183
9. Lizza BD, Rhodes NJ, Esterly JS, Toy C, Lopez J, Scheetz MH (2016) Impact of body mass index on clinical outcomes in patients with gram-negative bacteria bloodstream infections. J Infect Chemother 22(10):671–676
10. Laupland KB, Zingg W (2021) More is not better: the complicated relationship between obesity, critical illness, and infection. Intensive Care Med 47(4):467–469
11. Paulsen J, Askim A, Mohus RM, Mehl A, Dewan A, Solligård E et al (2017) Associations of obesity and lifestyle with the risk and mortality of bloodstream infection in a general population: a 15-year follow-up of 64 027 individuals in the HUNT Study. Int J Epidemiol 46(5):1573–1581
12. Rogne T, Solligård E, Burgess S, Brumpton BM, Paulsen J, Prescott HC et al (2020) Body mass index and risk of dying from a bloodstream infection: a Mendelian randomization study. PLoS Med 17(11):e1003413
13. Queensland Health. The health of Queenslanders 2020. Report of the Chief Health Officer Queensland Brisbane: Queensland Government; 2020 [February 22nd, 2022. Available from: https://www.health.qld.gov.au/__data/assets/pdf_file/0019/1011286/choreport-2020-full.pdf. Accessed 16 May 2022
14. Leal J, Gregson DB, Ross T, Flemons WW, Church DL, Laupland KB (2010) Development of a novel electronic surveillance system for monitoring of bloodstream infections. Infect Control Hosp Epidemiol 31(7):740–747
15. Australian Bureau of Statistics. The Australian statistical geography standard (ASGS) remoteness structure 2018. Available from: https://www.abs.gov.au/website/ds/d3310114.nsf/home/remoteness+structure. Accessed 25 May 2022
16. Laupland KB, Stewart AG, Edwards F, Harris P, Heney C, George N et al (2022) Pasturella species bloodstream infections in Queensland, Australia, 2000–2019. Eur J Clin Microbiol Infect Dis 41(4):609–614. https://doi.org/10.1007/s10096-022-04411-w
17. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383
18. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC et al (2005) Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43(11):1130–1139
19. Chowdhury MZI, Turin TC (2020) Variable selection strategies and its importance in clinical prediction modelling. Fam Med Community Health 8(1):e000262
20. Kovesdy CP, Furth S, Zoccali C (2017) Obesity and kidney disease: hidden consequences of the epidemic. Physiol Int 104(1):1–14
21. Powell-Wiley TM, Poirier P, Burke LE, Després JP, Gordon-Larsen P, Lavie CJ et al (2021) Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 143(21):e984–e1010
22. Laupland KB, Pasquill K, Dagasso G, Parfitt EC, Steele L, Schonheyder HC (2020) Population-based risk factors for community-onset bloodstream infections. Eur J Clin Microbiol Infect Dis 39(4):753–758
23. Laupland KB, Edwards F, Ramanan M, Shekar K, Tabah A (2021) Reconciling the obesity paradox: obese patients suffer the highest critical illness associated mortality rates. J Crit Care 66:75–77
24. Di Bella AL, Comans T, Gane EM, Young AM, Hickling DF, Lucas A et al (2020) Underreporting of obesity in hospital inpatients: a comparison of body mass index and administrative documentation in Australian hospitals. Healthcare (Basel) 8(3):334. https://doi.org/10.3390/healthcare8030334

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.